Skip to main content

Rheumatoid Arthritis Testing Market Report 2021-2028 | Size, Share, Growth, Trends, Analysis, Competitive Landscape, Revenue, Forecast

Written by Customer Service on . Posted in Mergers And Acquisitions.

Top Players Covered in the Rheumatoid Arthritis Testing Market Research Report include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Beckman Coulter, Inc., Siemens Healthcare GmbH, Microdrop LLC (imaware), Augurex Life Sciences Corp., Qiagen, Svar Life Science AB (Euro Diagnostica), Exagen Inc., Aviva Systems Biology Corporation, Bio-Rad Laboratories Inc and Other Market Players

Pune, India, Aug. 02, 2021 (GLOBE NEWSWIRE) — The global rheumatoid arthritis testing market will derive growth from the high prevalence of the disease across the world. According to a report by Fortune Business Insights, titled “Rheumatoid Arthritis Testing Market Size, Share & Industry Analysis, By Test Type (Serological Tests, Rheumatoid Arthritis Severity Tests & Medication Monitoring Tests, Imaging Tests), By End User (Hospitals & Clinics, Diagnostic Centers, Others) and Regional Forecast, 2019-2026,” the market will benefit from recent technological advancements in testing equipment associated with diagnosis of the disease.

Rheumatoid arthritis is a long term severe disorder that directly affects the immune system of the human body. It is a serious disorder that comes with side effects such as swelling and inflammation around the affected area. Moreover, excessive pain is caused within body joints and organs of the body. The disease can affect several joints in the body, which in turn has led to a severe emphasis on the research and development of treatment options associated with the disease.


Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/rheumatoid-arthritis-testing-market-101523

As joints are directly responsible for body movements and labor, there is a huge need for efficient treatment methods. According to the Rheumatoid Arthritis Support Network, around 1.3 million people in the United States are affected by the disease, which accounts for nearly 1% of the global population. Such a high prevalence of the disease will open up a huge potential for growth for the companies operating in the market. The report analyzes ongoing market trends and discusses the current scenario, with primary focus on aspects such as competitive landscape, growth drivers, and major product launches in recent years.

Driven by High Prevalence of Rheumatoid Arthritis, North America to Emerge as the Leading Region

The report segments the market based on regional demographics into North America, Latin America, Europe, Middle East and Africa, and Asia Pacific. Among these regions, North America will emerge as the leading region in the coming years, mainly attributable to the growing prevalence of rheumatoid arthritis in this region.

According to the Centers for Disease Control and Prevention, by 2040, around 78.4 million people across the world will be diagnosed with the disease. Furthermore, an estimated 34.6 million people will report activity limitations due to rheumatoid arthritis. This will contribute to the growth of the market in North America.


For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/rheumatoid-arthritis-testing-market-101523


Advances in Treatment Methods to Favor Market Growth

The growing penetration of technology in the healthcare industry has given rise to exceptional treatment methods. Technology has bettered the treatment and diagnosis methods associated with rheumatoid arthritis. As a result, the demand for rheutmatoid arthritis test equipment has increased drastically in recent years. Technological advancements have yielded benefits such as improved patient outcomes, accurate diagnosis and testing procedures, ease of use, and reduce cost for testing. In 2019, Microdrop LLC announced the launch of a new arthritis screening method, wherein patients would be able to avail testing methods from the comfort of their homes.

This eliminates the need for hospital visits and huge favors patients who are either bedridden or have physical disabilities. Microdrop’s latest product will help the company generate a substantial amount of rheumatoid arthritis testing market revenue in the coming years. This, in turn, will influence the growth of the market in a positive way.


Quick Buy –  Rheumatoid Arthritis Testing Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/101523


Driven by High Prevalence of Rheumatoid Arthritis, North America to Emerge as the Leading Region

The report segments the market based on regional demographics into North America, Latin America, Europe, Middle East and Africa, and Asia Pacific. Among these regions, North America will emerge as the leading region in the coming years, mainly attributable to the growing prevalence of rheumatoid arthritis in this region. According to the Centers for Disease Control and Prevention, by 2040, around 78.4 million people across the world will be diagnosed with the disease. Furthermore, an estimated 34.6 million people will report activity limitations due to rheumatoid arthritis. This will contribute to the growth of the market in North America.

List of the Companies Profiled in the Global Market:

  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd.
  • Beckman Coulter, Inc.
  • Siemens Healthcare GmbH
  • Microdrop LLC (imaware)
  • Augurex Life Sciences Corp.
  • Qiagen
  • Svar Life Science AB (Euro Diagnostica)
  • Exagen Inc.
  • Aviva Systems Biology Corporation
  • Bio-Rad Laboratories Inc.


Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/rheumatoid-arthritis-testing-market-101523


Segmentation:

By Test Type        

  • Serological Tests
  • Erythrocyte Sedimentation Rate (ESR)
  • Anti-Cyclic Citrullinated Peptide (anti-CCP)
  • Rheumatoid Factor (RF)
  • C-reactive Protein (CRP)
  • Anti-nuclear antibody (ANA)
  • Uric Acid
  • Others
  • Rheumatoid Arthritis Severity Tests & Medication Monitoring Tests
  • Salicylate Level Test
  • Muscle Enzyme Test
  • Creatinine Test
  • Multibiomarker Disease Activity (MBDA)
  • Imaging Tests
  • MRI
  • X-Ray
  • Ultrasound

By End User         

  • Hospitals & Clinics
  • Diagnostic Centers
  • Others

By Geography      

  • North America (USA and Canada)
  • Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)


Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/rheumatoid-arthritis-testing-market-101523


About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.


Contact Us:

Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.

Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.